Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae.

Lundberg U, Senn BM, Schüler W, Meinke A, Hanner M.

Hum Vaccin Immunother. 2013 Mar;9(3):497-505. Epub 2012 Dec 18.

2.

Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner.

Senn BM, Visram Z, Meinke AL, Neubauer C, Gelbmann D, Sinzinger J, Hanner M, Lundberg U, Boisvert H, Reinscheid D, von Gabain A, Nagy E.

Vaccine. 2011 May 31;29(24):4116-24. doi: 10.1016/j.vaccine.2011.03.100. Epub 2011 Apr 13.

PMID:
21496467
3.

Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens.

Meinke AL, Senn BM, Visram Z, Henics TZ, Minh DB, Schüler W, Neubauer C, Gelbmann D, Noiges B, Sinzinger J, Hanner M, Dewasthaly S, Lundberg U, Hordnes K, Masoud H, Sevelda P, von Gabain A, Nagy E.

Vaccine. 2010 Oct 8;28(43):6997-7008. doi: 10.1016/j.vaccine.2010.08.041. Epub 2010 Aug 21.

PMID:
20732466
4.

Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.

Fritzer A, Senn BM, Minh DB, Hanner M, Gelbmann D, Noiges B, Henics T, Schulze K, Guzman CA, Goodacre J, von Gabain A, Nagy E, Meinke AL.

Infect Immun. 2010 Sep;78(9):4051-67. doi: 10.1128/IAI.00295-10. Epub 2010 Jul 12.

5.

The pneumococcal eukaryotic-type serine/threonine protein kinase StkP co-localizes with the cell division apparatus and interacts with FtsZ in vitro.

Giefing C, Jelencsics KE, Gelbmann D, Senn BM, Nagy E.

Microbiology. 2010 Jun;156(Pt 6):1697-707. doi: 10.1099/mic.0.036335-0. Epub 2010 Mar 11.

PMID:
20223804
6.

Impaired antibody response causes persistence of prototypic T cell-contained virus.

Bergthaler A, Flatz L, Verschoor A, Hegazy AN, Holdener M, Fink K, Eschli B, Merkler D, Sommerstein R, Horvath E, Fernandez M, Fitsche A, Senn BM, Verbeek JS, Odermatt B, Siegrist CA, Pinschewer DD.

PLoS Biol. 2009 Apr 7;7(4):e1000080. doi: 10.1371/journal.pbio.1000080. Erratum in: PLoS Biol. 2009 Aug;7(8). doi: 10.1371/annotation/42dca769-eca8-4e8f-a6b5-236355b631ff.

7.

Polyclonal and specific antibodies mediate protective immunity against enteric helminth infection.

McCoy KD, Stoel M, Stettler R, Merky P, Fink K, Senn BM, Schaer C, Massacand J, Odermatt B, Oettgen HC, Zinkernagel RM, Bos NA, Hengartner H, Macpherson AJ, Harris NL.

Cell Host Microbe. 2008 Oct 16;4(4):362-73. doi: 10.1016/j.chom.2008.08.014.

8.

Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies.

Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, Gelbmann D, Lundberg U, Senn BM, Schunn M, Habel A, Henriques-Normark B, Ortqvist A, Kalin M, von Gabain A, Nagy E.

J Exp Med. 2008 Jan 21;205(1):117-31. doi: 10.1084/jem.20071168. Epub 2007 Dec 31.

9.

Long-term maternal imprinting of the specific B cell repertoire by maternal antibodies.

Fink K, Zellweger R, Weber J, Manjarrez-Orduno N, Holdener M, Senn BM, Hengartner H, Zinkernagel RM, Macpherson AJ.

Eur J Immunol. 2008 Jan;38(1):90-101.

10.

B cell activation state-governed formation of germinal centers following viral infection.

Fink K, Manjarrez-Orduño N, Schildknecht A, Weber J, Senn BM, Zinkernagel RM, Hengartner H.

J Immunol. 2007 Nov 1;179(9):5877-85.

11.

Dendritic cell-independent B cell activation during acute virus infection: a role for early CCR7-driven B-T helper cell collaboration.

Scandella E, Fink K, Junt T, Senn BM, Lattmann E, Förster R, Hengartner H, Ludewig B.

J Immunol. 2007 Feb 1;178(3):1468-76.

12.

Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses.

Fink K, Lang KS, Manjarrez-Orduno N, Junt T, Senn BM, Holdener M, Akira S, Zinkernagel RM, Hengartner H.

Eur J Immunol. 2006 Aug;36(8):2094-105.

13.

Natural IgE production in the absence of MHC Class II cognate help.

McCoy KD, Harris NL, Diener P, Hatak S, Odermatt B, Hangartner L, Senn BM, Marsland BJ, Geuking MB, Hengartner H, Macpherson AJ, Zinkernagel RM.

Immunity. 2006 Mar;24(3):329-39.

14.

Deliberate removal of T cell help improves virus-neutralizing antibody production.

Recher M, Lang KS, Hunziker L, Freigang S, Eschli B, Harris NL, Navarini A, Senn BM, Fink K, Lötscher M, Hangartner L, Zellweger R, Hersberger M, Theocharides A, Hengartner H, Zinkernagel RM.

Nat Immunol. 2004 Sep;5(9):934-42. Epub 2004 Aug 8.

PMID:
15300247
15.

Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies.

Hangartner L, Senn BM, Ledermann B, Kalinke U, Seiler P, Bucher E, Zellweger RM, Fink K, Odermatt B, Bürki K, Zinkernagel RM, Hengartner H.

Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12883-8. Epub 2003 Oct 20.

16.

Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections.

Senn BM, López-Macías C, Kalinke U, Lamarre A, Isibasi A, Zinkernagel RM, Hengartner H.

Eur J Immunol. 2003 Apr;33(4):950-61.

17.

Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence.

Seiler P, Senn BM, Klenerman P, Kalinke U, Hengartner H, Zinkernagel RM.

J Virol. 2000 Jul;74(13):5896-901.

18.

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Ciurea A, Klenerman P, Hunziker L, Horvath E, Senn BM, Ochsenbein AF, Hengartner H, Zinkernagel RM.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2749-54.

20.

Supplemental Content

Support Center